Clinical Pharmacology & Therapeutics · 2006 · 98 citations · 26 references
OATP1B1 is a meaningful factor for atrasentan disposition. Individuals may be classified as having extensive, intermediate, or poor OATP1B1 transport phenotypes according to SLCO1B1 genotypes. Increased exposures of OATP1B1 substrates might be expected in individuals who have the poor transporter phenotype or are treated with an OATP1B1 inhibitor.
26
Sven Hoffmeyer, Oliver Burk, Oliver von Richter et al. · Proceedings of the National Academy of Sciences · 2000 · 2.4K citations